To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Catalyst Biosciences Announces Agreement with MedImmune to Discover and Develop Engineered Protease Therapeutics
Read time: Less than a minute
Catalyst Biosciences, Inc. has announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases.
Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments totaling up to $195 million, exclusive of royalty payments, for the development of drug candidates against two distinct targets.
Through the collaboration, MedImmune will support the discovery research and preclinical development by Catalyst of Alterase™ therapeutics against an undisclosed target, with an option to expand the agreement to include a second target.
Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins. MedImmune will be responsible for all development, manufacturing, and commercialization efforts associated with the products discovered through the collaboration in exchange for future milestones and royalties.
"We are very pleased to add MedImmune, a leading developer of biologic therapies, as a partner," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Our Alterase drug discovery engine is creating novel next-generation protein therapeutics against a broad variety of important disease targets. Collaborations such as this demonstrate the high value of our discovery and protein engineering capabilities."
Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments totaling up to $195 million, exclusive of royalty payments, for the development of drug candidates against two distinct targets.
Through the collaboration, MedImmune will support the discovery research and preclinical development by Catalyst of Alterase™ therapeutics against an undisclosed target, with an option to expand the agreement to include a second target.
Alterase therapeutics are next-generation, protease biologics engineered with the ability to catalytically cleave and inactivate disease-causing proteins. MedImmune will be responsible for all development, manufacturing, and commercialization efforts associated with the products discovered through the collaboration in exchange for future milestones and royalties.
"We are very pleased to add MedImmune, a leading developer of biologic therapies, as a partner," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Our Alterase drug discovery engine is creating novel next-generation protein therapeutics against a broad variety of important disease targets. Collaborations such as this demonstrate the high value of our discovery and protein engineering capabilities."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
